ScholarIQanswers from OpenAlex & ORCID
Lisa M. Landrum
ResearcherPublications, citations & collaboration network
Lisa M. Landrum is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Lisa M. Landrum have?
ScholarIQindexed works
Lisa M. Landrum has 202 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lisa M. Landrum have?
ScholarIQcitation count
Lisa M. Landrum has 35,389 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Lisa M. Landrum?
ScholarIQh-index
Lisa M. Landrum has an h-index of 52 in OpenAlex.
What is the i10-index of Lisa M. Landrum?
ScholarIQi10-index
Lisa M. Landrum has an i10-index of 85 in OpenAlex.
What is the ORCID of Lisa M. Landrum?
ScholarIQorcid
The ORCID for Lisa M. Landrum is on the source record.
What is the OpenAlex record for Lisa M. Landrum?
ScholarIQopenalex
The OpenAlex for Lisa M. Landrum is on the source record.
What are the most-cited papers on Lisa M. Landrum?
ScholarIQmost cited works
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Bradley J. Monk
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, René dePont Christensen, Zoltán Novàk, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M. Landrum, Lars Hanker, Ashley Stuckey, Ingrid Boere, Michael A. Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn K. McCourt, Francesco Raspagliesi, Mark S. Shahin, Sarah Gill, Bradley J. Monk, Joseph Buscema, Thomas J. Herzog, Larry J. Copeland, Min Tian, Zangdong He, Shadi Stevens, Eleftherios Zografos, Robert L. Coleman, Matthew A. Powell
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, Guilherme Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily Hinchcliff, Shashikant Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Philip J. DiSaia, Larry J. Copeland, William T. Creasman, Frederick B. Stehman, Mark F. Brady, Robert A. Burger, J.T. Thigpen, Michael J. Birrer, Steven Waggoner, David H. Moore, Katherine Y. Look, Wui-Jin Koh, Bradley J. Monk
Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass
Richard G. Moore, Michael Craig Miller, Paul DiSilvestro, Lisa M. Landrum, W Gajewski, John J. Ball, Steven J. Skates